Topic:

Partnering

Latest Headlines

Latest Headlines

Venrock unveils a $450M new fund with eyes on biotech

Well-heeled venture capital firm Venrock has pieced together a 7th fund, banking $450 million in new investments as it sets out to grow its portfolio of promising startups.

Sanofi, Regeneron pay $67M for a shortcut in the blockbuster PCSK9 race with Amgen

Sanofi and Regeneron just stole a march on Amgen in the race to get their PCSK9 cardio drug through the FDA and onto the market. The two companies revealed Wednesday evening that they had picked up a priority review voucher BioMarin had won for a recent rare disease drug approval, paying $67.5 million for the regulatory shortcut. They'll split the cost and share in the benefit, shaving four months off the regulatory review time for alirocumab.

Gilead bags a portfolio of HIV-neutralizing antibodies

Gilead has picked up the exclusive rights to develop a set of HIV-neutralizing antibodies discovered at Theraclone in collaboration with the International AIDS Vaccine Initiative and The Scripps Research Institute. Seattle-based Theraclone, which used its tech platform I-STAR in the project, picked up an unspecified set of milestones and an upfront payment in the deal.

Japan's Konica Minolta, New Jersey Dx outfit to develop heart attack rapid blood test

Japanese tech giant Konica Minolta sealed an agreement with a New Jersey diagnostics outfit to develop a test that can rapidly detect early cardiac muscle tissue damage after heart attacks strike.

Sanofi dumps KaloBios' antibiotic in another stinging setback

KaloBios was an early entrant in 2013's boom of biotech IPOs, touting its development technology as a springboard for high-quality antibodies. A year later, that promise hasn't come to fruition, and partner Sanofi is walking away from an antibacterial program for which the company had high hopes.

AstraZeneca reaches out to Roche with a would-be cancer blockbuster

AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $3 billion a year at its peak, and the drugmaker is working with rival Roche to craft a blood test that can spot ideal patients for the therapy.

Otsuka, Horizon team up on early-stage development

Horizon Discovery, which makes its money providing development expertise to drugmakers, has signed a deal with Otsuka Pharmaceutical to apply its technology to some early-phase treatments.

Medtronic teaming up with China's LifeTech to develop cardiovascular products

Medtronic is teaming up with LifeTech Scientific to manufacture and distribute cardiac devices for China's growing cardiovascular market.

Icon will teach Cambridge students how to market drugs

Global CRO Icon has deepened its longstanding relationship with Cambridge University, agreeing to lead a class on pricing and market access for new drugs.

TransCelerate taps Cognizant to get its Big Pharma backers on the same page

TransCelerate BioPharma, a nonprofit run by 19 of the world's largest drugmakers, formed two years ago to help Big Pharma share resources and stop wasting time and money on noncompetitive work. Now, the group is looking to create a novel platform to standardize how clinical trial sites communicate with sponsors, choosing contractor Cognizant to develop it.